brivaracetam
| Title | Journal |
|---|---|
| Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. | Epilepsia 20160201 |
| Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission. | Scientific reports 20160101 |
| Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Recent and future antiepileptic drugs and their impact on cognition: what can we expect? | Expert review of neurotherapeutics 20120601 |
| Clavulanic acid does not affect convulsions in acute seizure tests in mice. | Journal of neural transmission (Vienna, Austria : 1996) 20120101 |
| Rational polytherapy in the treatment of acute seizures and status epilepticus. | Epilepsia 20111001 |
| Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. | European journal of pharmacology 20110816 |
| Brivaracetam for the treatment of epilepsy. | Expert opinion on pharmacotherapy 20110801 |
| Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. | Epilepsia 20110201 |
| Pharmacotherapy of epilepsy: newly approved and developmental agents. | CNS drugs 20110201 |
| Increased compactibility of acetames after roll compaction. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110101 |
| Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). | Epilepsy research 20101201 |
| New drugs for pediatric epilepsy. | Seminars in pediatric neurology 20101201 |
| Emerging drugs for partial onset seizures. | Expert opinion on emerging drugs 20100901 |
| Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. | Epilepsy research 20100901 |
| Antiepileptic drug interactions - principles and clinical implications. | Current neuropharmacology 20100901 |
| Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. | Neurology 20100810 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100401 |
| Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. | Drugs of today (Barcelona, Spain : 1998) 20100401 |
| Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. | Basic & clinical pharmacology & toxicology 20100301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100301 |
| Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. | Drugs 20100212 |
| Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression. | ChemMedChem 20100201 |
| Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. | Epilepsy research 20100101 |
| What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. | Epilepsia 20091201 |
| Brivaracetam inhibits spreading depression in rat neocortical slices in vitro. | Seizure 20090701 |
| Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). | Epilepsy research 20090101 |
| SVOP is a nucleotide binding protein. | PloS one 20090101 |
| Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. | Pharmacological reports : PR 20090101 |
| Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. | European journal of pharmacology 20081228 |
| Debate: Does genetic information in humans help us treat patients? PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. | Epilepsia 20081201 |
| Treatment of Lennox-Gastaut syndrome: overview and recent findings. | Neuropsychiatric disease and treatment 20081201 |
| Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. | British journal of pharmacology 20080801 |
| Brivaracetam: a rational drug discovery success story. | British journal of pharmacology 20080801 |
| Effect of brivaracetam on cardiac repolarisation--a thorough QT study. | Current medical research and opinion 20080801 |
| The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. | British journal of clinical pharmacology 20080701 |
| New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. | Current neurology and neuroscience reports 20080701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080401 |
| Brivaracetam: a new drug in development for epilepsy and neuropathic pain. | Expert opinion on investigational drugs 20080301 |
| The effectiveness of anticonvulsants in psychiatric disorders. | Dialogues in clinical neuroscience 20080301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080301 |
| Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. | Drug metabolism and disposition: the biological fate of chemicals 20080101 |
| Pharmacological management of epilepsy: recent advances and future prospects. | Drugs 20080101 |
| Modifications of antiepileptic drugs for improved tolerability and efficacy. | Perspectives in medicinal chemistry 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. | Neurology 20070904 |
| The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. | British journal of clinical pharmacology 20070601 |
| [A new aspect in the research on antiepileptic drugs]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070201 |
| Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). | Epilepsy research 20070101 |
| Brivaracetam (UCB 34714). | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070101 |
| Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. | Journal of neural transmission (Vienna, Austria : 1996) 20070101 |
| Diverse mechanisms of antiepileptic drugs in the development pipeline. | Epilepsy research 20060601 |
| New antiepileptic drugs that are second generation to existing antiepileptic drugs. | Expert opinion on investigational drugs 20060601 |
| Brivaracetam UCB. | Current opinion in investigational drugs (London, England : 2000) 20050701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Antiepileptic drug discovery: lessons from the past and future challenges. | Acta neurologica Scandinavica. Supplementum 20050101 |
| Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. | Journal of medicinal chemistry 20040129 |
| Symposium: the city: a viable environment for the elderly? Phase III: planning and delivery of health services. Background. | The Gerontologist 19760201 |